Category - Executive Moves

Executive Moves

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

Closely-held Ripple Therapeutics appointed Jonathan Talamo, M.D., currently a member of the board, to be chairman. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology, with...

November 29, 2022

Executive Moves

JD Finley named interim CEO of Palisade Bio

Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10. In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development...

October 11, 2022

Executive Moves

Kumaraguru Raja joins ROTH healthcare research team

Kumaraguru Raja, Ph.D., joined ROTH Capital Partners healthcare research team, as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...

October 11, 2022

Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...

October 4, 2022

Executive Moves

Paul Brennan steps down as CEO of NervGen

Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...

September 23, 2022

Executive Moves

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...

August 16, 2022

Executive Moves

Titan Pharma names new CEO, expands board

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Activist Investing’s David Lazar as interim chairman and CEO, with a mandate to lead Titan’s continuing review of strategic alternatives. He succeeds Marc Rubin, M.D...

August 16, 2022

Executive Moves

Enzo Biochem appoints Matthew Kupferberg as general counsel

Enzo Biochem (NYSE:ENZ) named Matthew Kupferberg as the company’s in-house general counsel. He was most recently general counsel, chief compliance officer and privacy officer of Digital Medical Technologies, a...

August 3, 2022

Executive Moves

DURECT names Timothy Papp as CFO

DURECT (NASDAQ:DRRX) appointed Timothy Papp as chief financial officer to direct and oversee all financial and capital markets activities, including accounting, financial reporting, financial planning and analysis...

July 5, 2022

Executive Moves

Zymeworks names Paul Moore as CSO

Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...

June 28, 2022

Category - Executive Moves

Subscribe